Pool Re Selects Clearwater Analytics to Modernize Investment Operations and Risk Management
UK’s Terrorism Reinsurer Adopts Clearwater Platform to Streamline Accounting and Elevate Risk Analytics
Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced that Pool Re, the UK’s terrorism reinsurer overseeing more than £7.2 billion in assets, has selected Clearwater to modernize its investment operations, accounting, and risk management infrastructure.
After a 2024 tender process, Pool Re adopted Clearwater’s platform as its Investment Accounting Book of Record and has since expanded its use to include advanced risk analytics, including scenario and shock analysis, to support the management of investment risk exposure.
“Clearwater’s platform plays an important role within our investment and finance operations. It gives us the precision and speed we need to support robust investment decision making, as we steer the investment portfolio in support of our ultimate mission of providing financial protection to the UK economy against the risk of terrorism,” said Rich Roberts, Chief Finance and Investment Officer of Pool Re. “The platform integrates complex investment data, compliance, and risk calculations into a single, automated solution—something that previously required multiple systems and manual reconciliation. After a smooth implementation, we’re now fully operational and leveraging Clearwater for advanced risk analytics to better assess scenarios and make faster, more confident decisions.”
The implementation introduces significant advancements to Pool Re’s investment management operations:
- Sophisticated risk assessment through scenario and shock analysis
- Data-driven strategic decision making powered by validated, accurate information
- Automated reporting and compliance monitoring
- Integrated performance measurement
“Institutional investors need speed, accuracy, and real-time insight to navigate today’s complex markets,” said Keith Viverito, Managing Director, EMEA at Clearwater Analytics. “This partnership with Pool Re shows how Clearwater helps leading organizations streamline operations, eliminate manual processes, and access comprehensive risk analytics—all from a single platform.”
To learn how Clearwater Analytics can elevate your investment management strategy and drive operational excellence, speak to an expert today.
About Pool Re
Pool Re is the insurance industry’s mutual for reinsuring terrorism risk in Great Britain and an Arm’s Length Body of HM Treasury (HMT). It exists to protect Britain’s economy and safeguard society and livelihoods from acts of terrorism.
Pool Re offers commercial property reinsurance cover for losses caused by terrorism on an “All Risks” basis, including chemical, biological, radiological and nuclear (CBRN), damage caused by remote digital interference and non-damage business interruption. It offers a financial safety net for more than £2.2 trillion of assets belonging to businesses of all sizes.
Pool Re has a reserve fund built up over 30 years by investing insurers’ premium contributions in preparation for the unthinkable. Pool Re is also backed by an unlimited HMT loan facility which underpins its work to support the resilience of the British economy. For more information, visit www.poolre.co.uk.
About Clearwater Analytics
Clearwater Analytics (NYSE: CWAN) is transforming investment management with the industry's most comprehensive cloud-native platform for institutional investors across global public and private markets. While legacy systems create risk, inefficiency, and data fragmentation, Clearwater's single-instance, multi-tenant architecture delivers real-time data and AI-driven insights throughout the investment lifecycle. The platform eliminates information silos by integrating portfolio management, trading, investment accounting, reconciliation, regulatory reporting, performance, compliance, and risk analytics in one unified system. Serving leading insurers, asset managers, hedge funds, banks, corporations, and governments, Clearwater supports over $8.8 trillion in assets globally. Learn more at www.clearwateranalytics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610948543/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KAYTUS Unveils Upgraded MotusAI to Accelerate LLM Deployment12.6.2025 13:11:00 CEST | Press release
Streamlined inference performance, tool compatibility, resource scheduling, and system stability to fast-track large AI model deployment. KAYTUS, a leading provider of end-to-end AI and liquid cooling solutions, today announced the release of the latest version of its MotusAI AI DevOps Platform at ISC High Performance 2025. The upgraded MotusAI platform delivers significant enhancements in large model inference performance and offers broad compatibility with multiple open-source tools covering the full lifecycle of large models. Engineered for unified and dynamic resource scheduling, it dramatically improves resource utilization and operational efficiency in large-scale AI model development and deployment. This latest release of MotusAI is set to further accelerate AI adoption and fuel business innovation across key sectors such as education, finance, energy, automotive, and manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/
FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 202512.6.2025 13:00:00 CEST | Press release
FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letterIf approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74
Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event12.6.2025 13:00:00 CEST | Press release
Experts from Qualcomm, Viant Medical, and Thermo Fisher Scientific join Kinaxis and economic futurist Andrew Busch to share insights on navigating tariff volatility As global trade tensions remain at the forefront of business decision-making,Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern. Titled, Tariffs, Trade, and Turbulence: How to Respond to Today’s Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today’s volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains. “We’re witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what’s comin
BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 202512.6.2025 12:00:00 CEST | Press release
Clinical results from next-generation investigational therapies demonstrate potential for deep, durable responses that support the advancement of pivotal studies and future regulatory filingsPhase 1 study of BCL2 inhibitor sonrotoclax plus BRUKINSA® elicited deep responses – 96% ORR in R/R CLL and 79% ORR in R/R MCL patients – with no new safety signals in the latest resultsBTK degrader BGB-16673 shows strong early results in hard-to-treat populations BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will present new clinical data from three cornerstone hematology assets at the European Hematology Association (EHA) Congress. Four oral presentations highlight the promising clinical activity of BeOne’s next-generation BCL2 inhibitor sonrotoclax, BTK protein degrader BGB-16673, and the backbone of our hematology franchise, BTK inhibitor BRUKINSA (zanubrutinib), which has the broadest label globally of any approved BTK inhibitor. These data reinforce
Infobip Named Among Top 75 in Fortune’s Europe’s Most Innovative Companies 202512.6.2025 10:17:00 CEST | Press release
Fortune ranking aligns with Infobip’s innovative efforts in the IT industry and digital infrastructure Global communications platform Infobiphas been recognized among the top 75 companies in Fortune’s inaugural ranking of Europe’s Most Innovative Companies for 2025. It holds the position of number 68, placing it in the top 25% of all listed companies. This distinction reflects Infobip’s ongoing commitment to advancing Europe’s IT sector and digital infrastructure through cutting-edge innovation. The first Fortune Europe’s Most Innovative Companies list, created in collaboration with Statista, evaluated 300 companies from 21 countries and 16 industries based on innovation culture, product development, and process improvements. Infobip is at the forefront of Europe’s digital transformation. Infobip participates in the IPCEI-CIS project, which aims to build the next-generation global communications platform, thereby reinforcing Europe’s competitiveness in the tech sector. Infobip’s involv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom